Dec 7 (Reuters) – Drugmaker Gilead Sciences Inc
said on Thursday it was acquiring privately-held Cell Design
Labs Inc for up to $567 million, giving it access to new
technology platforms that would help in the development of
cancer drugs.

Read More At Article Source | Article Attribution